AKT1 and hepatocellular carcinoma: Then, to examine the synergistic mechanisms of PPa extract plus sorafenib and the results revealed that the combinational treatment reinforced to reduce the AKT/mTOR pathway and level of ERK, indicated that PPa extract plus sorafenib might be induce more ROS production than drug alone to repress HCC cell growth and reduce the potential of sorafenib-resistant development on AKT/mTOR and ERK pathway.